Avacta (AVCT) at ShareSoc 13.3.19

Friday, Mar 15 2019 by
2

Avacta presentation at ShareSoc London 13.3.19
by Dr Alastair Smith

https://www.piworld.co.uk/2019/03/15/avacta-avct-presentation-at-sharesoc-london-13th-march-2019/

Dr Smith gives a comprehensive overview of AVCT, followed by the Q&A.

We'll also have ECSC to follow in due course.

Unlock this article instantly by logging into your account

Don’t have an account? Register for free and we’ll get out your way

Disclaimer:  

As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. The author may own shares in any companies discussed, all opinions are his/her own & are general/impersonal. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.


Do you like this Post?
Yes
No
2 thumbs up
0 thumbs down
Share this post with friends



Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics. more »

LSE Price
28.5p
Change
 
Mkt Cap (£m)
33.1
P/E (fwd)
n/a
Yield (fwd)
n/a



  Is LON:AVCT fundamentally strong or weak? Find out More »


Please subscribe to submit a comment






Stock Picking Tutorial Centre


Related Content



Mello 2019All you need to know
Mello 2019....All you need to know !
Events and Meetups 27th Feb

ShareSoc News
ShareSoc News
Learning to Invest 30th Nov '17


Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis